Clinical trials: Head Neck Cancer Squamous Cell Recurrent
Recurrent Cancer, Prostate Cancer
Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors
This study investiagates deep-regional or superficial hyperthermia to enhance radiotherapy or chemoradiation in patients that suffer recurrent disease after previous radiotherapy.
- Conditions
- Recurrent Cancer, Prostate Cancer, Cervical Cancer, Anal Cancer
- Trial name
- HETERERO (NCT04889742)
- Testing
- loco-regional hyperthermia
- Where
- Germany
- Volunteers
- 110 people
- Sponsor
- Charite University, Berlin, Germany
Head and Neck Squamous Cell Carcinoma
Study of SCB01A in Patient With Head and Neck Cancer
To evaluate the safety and efficacy of SCB01A in head and neck cancer.
- Trial name
- NCT02488629
- Testing
- SCB01A
- Where
- 5 sites in Taiwan
- Volunteers
- 5 people
- Sponsor
- SynCore Biotechnology Co., Ltd.
Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC
The entire treatment process is divided into two phases: Phase I SBRT combined with PD-1/CTLA-4 bispecific antibody (AK104) and Phase II AK104 single-agent maintenance therapy.
- Trial name
- NCT05732662
- Testing
- SBRT, Cadonilimab
- Volunteers
- 25 people
- Sponsor
- The First People's Hospital of Changzhou
Carcinoma, Squamous Cell, Head and Neck Neoplasms
Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)
The purpose of this study is to determine the safety and efficacy of an oral Farnesyl Protein Transferase Inhibitor (Lonafarnib/SCH 6636) as a single agent in Adult Patients With Squamous Cell Carcinoma of the Head \& Neck and…
- Trial name
- NCT00073450
- Testing
- Farnesyl Protein Transferase Inhibitor
- Volunteers
- 15 people
- Sponsor
- Merck Sharp & Dohme LLC
Esophageal Cancer
Peptide Vaccination in Treating Patients With Esophageal Cancer
The purpose of this study is to evaluate the safety and immunological monitoring for peptide vaccination therapy using novel cancer testis antigens for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma
- Trial name
- NCT00682227
- Testing
- TTK, LY6K, and IMP-3 peptides
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- University of Yamanashi
Head and Neck Cancer
Celecoxib in Treating Patients With Head and Neck Cancer That Can Be Removed By Surgery
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00357617
- Testing
- celecoxib, microarray analysis, protein expression analysis
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Head and Neck Cancer, Local Recurrent Tumor
Local Injection Methylene Blue Combined With Radiation in HNSCC Patients
The goal of this clinical trial is to investigate the effectiveness of Methylene Blue (MB) as a radiosensitizer in treating head and neck squamous cell carcinoma (HNSCC) that has recurred locally and is resistant to radiation…
- Trial name
- NCT07435415
- Testing
- Methylene Blue (50 mg/10ml)
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- China Medical University Hospital
Head and Neck Squamous Cell Carcinoma
Pembrolizumab in Combination with Flutamide Treatment for Recurrence / Metastasis HNSCC
This study is a single center, single arm clinical trial for newly diagnosed patients with locally advanced head and neck squamous cell carcinoma.
- Trial name
- NCT06694350
- Testing
- Pembrolizumab+Flutamide
- Volunteers
- 54 people
- Sponsor
- Zhejiang Provincial People's Hospital
Metastatic Head-and-neck Squamous-cell Carcinoma
Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin
This phase 2 study is designed to evaluate the safety and activity of TH-4000, a hypoxia-activated prodrug in participants with recurrent or metastatic squamous cell carcinoma of the head and neck or skin.
- Trial name
- NCT02449681
- Testing
- TH-4000 (Tarloxotinib)
- Where
- 10 sites in United States, Australia
- Volunteers
- 30 people
- Sponsor
- Rain Oncology Inc
Head and Neck Cancer, Precancerous/Nonmalignant Condition
Photodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract
RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, precancerous cells and cancer cells are killed.
- Trial name
- NCT00453336
- Testing
- Porfimer Sodium, Photodynamic Therapy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Miami
Squamous Cell Carcinoma of Esophagus
A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus
As a 2nd generation EGFR-TKI that irreversibly binds to EGFR receptors, afatinib showed the possibility of superior effects to 1st generation TKIs such as erlotinib and gefitinib.
- Trial name
- NCT02353936
- Testing
- BIBW2992
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Yonsei University
Head and Neck Cancer
A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic/Recurrent Head and Neck Cancer (HNSCC)
The purpose of this study is to determine if the combination of 2 chemotherapy drugs called pemetrexed and gemcitabine might be effective treatment for head and neck squamous cell cancer.
- Trial name
- NCT00589667
- Testing
- Pemetrexed plus Gemcitabine
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT00030498
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
This is a Phase II treatment, non-randomized, open label clinical trial to study the efficacy of the Cetuximab when administered as single agent in recurrent/ metastatic head and neck squamous cell carcinoma after the failure or…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma
- Trial name
- NCT04375384
- Testing
- Cetuximab, Questionnaire administration, Quality of life assessment
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Wake Forest University Health Sciences
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β).
- Trial name
- FORTIFI-FLEX (NCT07807163)
- Testing
- Ficerafusp alfa, Pembrolizumab (KEYTRUDA®)
- Where
- 7 sites in United States
- Volunteers
- 160 people
- Sponsor
- Bicara Therapeutics
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer
- Trial name
- NCT03538028
- Testing
- INCAGN02385
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Biosciences International Sàrl
Carcinoma, Squamous Cell of Head and Neck
Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy
The trial is designed as a multi-center, open label Phase 2 trial that investigates the efficacy and safety of Sym004 in subjects with squamous cell cancer of the head and neck (SCCHN).
- Trial name
- NCT01417936
- Testing
- Sym004
- Where
- 10 sites in Belgium, France and 1 more
- Volunteers
- 26 people
- Sponsor
- Symphogen A/S
Cancer
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499733
- Testing
- cyclophosphamide, Cryoablation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC
This study is a single center, non controlled, prospective phase II clinical trial to evaluate the efficacy and safety of Sacituzumab Tirumotecan and Toripalimab in the first-line treatment of recurrent/metastatic head and neck…
- Trial name
- NCT07088211
- Testing
- Sacituzumab Tirumotecan and Toripalimab
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
HNSCC
Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy
Head and neck cancer is the sixth most common cancer and more than 650,000 new cases are diagnosed each year worldwide. About 60% of the HNSCC patients present with unresectable locally advanced disease at diagnosis and treated…
- Trial name
- NCT02216916
- Testing
- HM781-36B
- Where
- South Korea
- Volunteers
- 49 people
- Sponsor
- Yonsei University